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BDNF homozygous floxed mice (BDNF lox+/+) are a transgenic mouse strain used 
to study the neurotrophin brain-derived neurotrophic factor (BDNF) through Cre-Lox 
recombination when crossed with the appropriate Cre-expressing strain. BDNF lox+/+ mice 
contain two artificially inserted LoxP sites located upstream and downstream from the 
BDNF coding region. This strain was originally described as physiologically normal and 
fertile by Rios et al., (2001). However, current literature lacks sufficient characterization 
and description of its behavioral phenotype. We utilized a three-stage behavioral protocol 
which included home cage monitoring observations, open-field, tail suspension, and 
acoustic PPI to provide a detailed behavioral phenotype for BDNF lox+/+ mice. Tail 
suspension protocols revealed progressive limb clasping deficits in BDNF lox+/+ mice 
compared to control genotypes. Importantly, the open-field test demonstrated increased 
locomotion in 150 d (150 day old) animals. Together these results suggest that clasping 
deficits are likely due to proprioceptive sensory neuropathy similar to those described by 
the mutant mouse strains cra1, loa and Swl (Chen et al., 2007; Dupuis et al., 2009; Zhao 
et al., 2016). Additionally, BDNF lox+/+ mice demonstrated increased PPI and evidence of 
stereotypy behaviors such as route tracing and somersaulting. We postulate that the 
neurological deficits presented by our data are produced by LoxP site transcriptional 
interference within the BDNF transcript. To support our hypothesis, future research 
should include quantification of BDNF expression, histological analysis of muscle 
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Neurodegenerative diseases are disorders of the nervous system that ultimately 
lead to the degeneration and death of neurons. Each neurodegenerative disease varies in 
pathology and clinical presentation, however, several of these disorders share similar 
cellular and molecular pathologies. These diseases include Alzheimer’s disease, 
Parkinson’s disease, multiple sclerosis, Huntington’s disease, Charcot-Marie Tooth 
disease, spinal-bulbar muscular atrophy (SBMA), and amyotrophic lateral sclerosis 
(ALS) (Bäumer et al., 2014; Braathen, 2012; Farrar et al., 2011; Jagot and Davoust, 2017; 
Lee et al., 2012; Rodríguez-Violante et al., 2017). Our research focuses on a 
neurodegenerative mouse model which previous data supports a resemblance to SBMA 
and ALS. We will discuss our research model in detail later in this review. 
SBMA is one of 9 neurodegenerative polygulatamine diseases (Shao and 
Diamond, 2007). SBMA pathology arises from a trinucleotide CAG expansion in the 
gene coding for androgen receptors (AR) (Beitel et al., 2013). Clinical presentation of 
SBMA is characterized by muscle atrophy, weakness in proximal limbs, contraction 
fasciculation, and neuron death (Katsuno et al., 2012). SBMA is X-linked and thus only 
observed in male populations. At the molecular level, misfolded AR proteins accumulate 
as nuclear inclusions where it is suggested to interfere with transcriptional regulation 
(Adachi et al., 2005). Amyotrophic lateral sclerosis (ALS), the most common clinical 
MND, is characterized by late-onset progressive degeneration of upper and lower motor 
neurons leading to paralysis and death from respiratory failure (Nichols et al., 2013). 
ALS shares genetic and cellular pathologies with frontotemporal dementia (Diekstra et 
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al., 2014). ALS is primarily a sporadic disease (sALS) which is responsible for 
approximately 90% of cases (Boylan, 2015; Renton et al., 2014). The pathophysiology of 
sALS remains largely misunderstood but dysfunctions in mitochondria, glutamate 
toxicity, and aberrant axonal transport are thought to play a role (Brunet et al., 2009; 
Grosskreutz et al., 2010; Ikenaka et al., 2012; Sasaki and Iwata, 2007; Smith et al., 2017). 
The remaining 10% of cases arise from single gene autosomal dominant transmission, 
known as familial inheritance (fALS). Notable genes linked to fALS and a small fraction 
of sALS include SOD1, C9orf72, TARDBP, and FUS. Mutations in the SOD1 gene, 
which encodes the enzyme superoxide dismutase 1, was the first genetic link to ALS 
(Deng et al., 1993; Rosen et al., 1993; Saccon et al., 2013). This mutation accounts for 
approximately 20% of fALS cases and 3% of sALS. SOD1 mutations in ALS patients are 
linked to progressive cellular pathology and lowered enzyme activity through either loss 
of function or gain of function in the protein (Grad et al., 2014; Pokrishevsky et al., 
2017). The gene associated with the largest percentage of ALS presentation is C9orf72. A 
toxic mutation in C9orf72 caused by a hexanucleotide GGGGCC repeat expansion 
accounts for about 40% of fALS and 10% of sALS patients (Majounie et al., 2012). (Farg 
et al., 2014; Ramesh and Pandey, 2017). The hexanucleotide expansion is suggested to 
cause dysfunctions in autophagy, the trafficking of waste vesicles to lysosomes (Farg et 
al., 2014; Ramesh and Pandey, 2017). In addition, nuclear proteins such as 
transactivation response element DNA binding-protein 43 (TDP-43), transcribed by the 
TARDBP gene, and FUS (fused in sarcoma RNA-binding protein) are prone to 
aggregation due to mutation. Mutations in TDP-43 accumulate as cytoplasmic inclusions 
in about 97% of ALS patients (Fallini et al., 2012; Lee et al., 2011, Johnson et al., 2009). 
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Moreover, mutations in FUS are associated with cytoplasmic localizations called stress 
granules which contain aggregations of protein fragments and mRNA (Bosco et al., 2010; 
Deng et al., 2014; Kwiatkowski et al., 2009; Vance et al., 2009). Heterozygous mutations 
in FUS directly account for the majority of juvenile forms of ALS (Bäumer et al., 2010). 
It is thought that cytoplasmic localizations and stress granules of TDP-43 and FUS 
disrupt protein function. Research shows that the various mutations may act 
synergistically rather than independently in ALS pathogenesis (Pokrishevsky et al., 
2016). In conclusion, neurodegenerative diseases such as SBMA and ALS are very 
complex diseases involving many genetic, cellular, and molecular factors. 
Neurons rely heavily on axonal transport to traffic vesicles containing cellular 
organelles, proteins, waste, and signaling proteins to and from the pre-synapse and 
dendrites (Ginty and Segal, 2002; Melkov et al., 2015; Schnapp and Reese, 1989; Sheetz 
et al., 1989). Axonal transport from the soma to the pre-synapse/dendrites is called 
anterograde transport, while transport from the distal pre-synapse/dendrites is referred to 
as retrograde transport. Axonal transport is performed by the molecular motor proteins 
kinesin and dynein which bind cargo containing cellular materials. Kinesin transports 
cargo in the anterograde direction, while dynein is primarily responsible for retrograde 
transport. Dynein is composed of several protein domains which include heavy chains, 
intermediate chains, intermediate light chains and light chain domains (Hall et al., 2010; 
Kardon et al., 2009). The heavy chain domains use ATP hydrolysis to move forward 
along the microtubules, while intermediate and light chains are involved attaching cargo 
vesicles. Additionally, the adaptor protein Dynactin-1 (DCTN-1) plays a crucial role in 
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attaching cargo vesicles and associating with microtubules (Moughamian and Holzbaur, 
2012).  
Dysfunctional retrograde transport has been identified in a number of 
neurodegenerative diseases such as Huntington’s disease, Charcot-Marie Tooth disease, 
SBMA, and ALS (Chevalier-Larsen and Holzbaur, 2006; Puls et al., 2005). Mutations in 
the dynein motor can impair retrograde transport and lead to aggregation of cell debris, 
failed trafficking of mitochondria, and loss of neurotrophin signaling (Ikenaka et al., 
2012; Magrané et al., 2014). Mouse models have significantly improved our 
understanding of the consequences of mutations in dynein. Katsuno et al., (2006) 
demonstrated that pathogenic AR inclusions accumulating in the nucleus play a role in 
the transcriptional dysregulation of the protein dynactin, disrupting axonal transport in an 
SBMA mouse model. The authors demonstrated that perturbation of axonal transport, 
lead to accumulation of phosphorylated neurofilament-H and synaptophysin at the distal 
ends of dendrites, as well as in muscle tissue. Moreover, the mutant mouse strains Legs at 
odd angles (Loa), Cramping 1 (Cra1), and Sprawling (Swl) all harbor various mutations 
in the dynein heavy chain 1 (Dync1h1) (Chen et al., 2007; Hafezparast et al., 2003). All 
three mutant strains are characterized by muscle weakness and clasping of their hind 
limbs. Early studies concluded motor neuron loss was responsible for the observed 
neuropathy, however, later studies report early-onset loss of proprioceptive sensory 
neurons primarily responsible for the degenerative pathology (Chen et al., 2007; Dupuis 
et al., 2009; Zhao et al., 2016). To understand the mechanism involved in the loss of 
sensory neurons in Swl mice, Zhao et al., (2016) applied Neural Growth Factor (NGF) to 
E.12.5 primary cultured neurons, a protein involved in the survival of neurons during 
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development (Buchman and Davies, 1993). The authors first applied NGF to the cell 
bodies of cultured mutant Swl and wild type neurons, which lead to cell survival. Next, 
NGF was applied only to the distal axons which lead to significant apoptosis in the Swl 
mutants. These data suggest that mutant dynein could not traffic NGF. Neurons rely on 
axonal transport for delivery of neurotrophins such as NGF (Cosker and Segal, 2014). 
Neurotrophins or neurotrophic factors, are a family of proteins which generally 
support neuron survival, differentiation, synaptic plasticity and developmental pruning 
(Bramham & Messaoudi, 2005; Hetman et al., 1999; Singh et al., 2008). The 
neurotrophin family includes nerve growth factor (NGF), neurotrophin-3 (NT-3), 
neurotrophin-4/5 (NT-4/5), and BDNF. Neurotrophins initiate their broad affects through 
the activation of the family of tropomysin-related (tyrosine) kinase receptors (Trks) and 
pan-neurotrophin receptor (p75 NTR) (Reichardt, 2006). There are three Trk receptor 
subtypes which hold specific binding affinities for each neurotrophin. TrkA preferentially 
binds NGF, TrkB binds BDNF and NT-4/5, while TrkC binds NT-3. Additionally, the 
p75 NTR, part of the tumor necrosis superfamily, is capable of binding to all neurotrophins. 
BDNF is the most well-characterized of the neurotrophins due to its many roles in the 
development and maturation of the nervous system (McAllister et al., 1995; Numakawa 
et al., 2010; Tyler and Pozzo-Miller, 2003). Like all neurotrophins, BDNF is first 
transcribed as a precursor protein, proBDNF (Lee et al., 2001; Mowla et al., 2001). The 
pro-region is located on the N-terminus of the protein. Mature BDNF is formed through 
cleavage of the pro region by the extracellular protease plasmin (Pang et al., 2004). Once 
sorted and trafficked for release, BDNF can be secreted through anterograde, retrograde, 
autocrine, or paracrine signaling (Adachi et al., 2005; Cheng et al., 2011; Polakowski et 
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al., 2014; Pruginin-Bluger et al., 1997). After secretion, BDNF in its mature and pro form 
bind to either TrkB or p75 NTR. These alternate forms of BDNF and receptor type 
promote different and sometimes opposing roles on the nervous system. 
Mature BDNF has a high affinity for the TrkB receptor (Numakawa et al., 2010). 
Upon binding, the BDNF/TrkB complex triggers several signaling pathways initiated by 
transphosphorylation of tyrosine residues on TrkBs cytoplasmic domain (Figure 1). 
Phosphorylated residues recruit scaffolding and adaptor proteins. For example, 
phosphorylation of residue site Y490 recruits Shc and Grb2 proteins respectively (Huang 
and Reichardt, 2003). This is followed by the binding of proteins such as Gab-1 or the 
guanine exchange factor son of sevenless (Sos). Sos activates the Ras protein which 
mediates downstream signaling of Phosphatidylinositol-4, 5-bisphosphate 3-kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) pathways. PI3K activated via Gab-
1 or Ras sends survival signals by activation of Akt kinases. Akt kinases further 
phosphorylate proteins such as BAD and cAMP response element-binding protein 
(CREB). Phosphorylation inhibits BAD, a pro-apoptosis protein, while phosphorylation 
of CREB promotes anti-apoptosis signals through activation of Bcl-2 family of proteins. 
Additionally, MAPK-associated pathways such as Raf-Mek-Erk promote survival 
through phosphorylation of Erk and activation of CREB (Zhao et al., 2017). BDNF/TrkB 
also recruits phospholipase C-y1 (PLC-y1) which hydrolyzes phosphatidylinositides 
forming diacylglycerol (DAG) and IP3 (Canossa et al., 2001). DAG activates PKC 
leading to activation of Mek1 and Erk1/2 and IP3. IP3 releases calcium stores initiating 
many calcium induced pathways including those regulated by calmodulin. 
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In contrast to the TrkB receptor, BDNF bound to p75 NTR initiates a complex of 
alternate downstream signaling pathways (Reichardt, 2006). These pathways can lead to 
survival, apoptosis, and axonal retraction (See Figure 1) (Li et al., 2017; Skeldal et al., 
2011; Taylor et al., 2012). Both pro and mature forms of BDNF bind to p75 NTR, however 
proBDNF has a significantly higher affinity for p75 NTR. When biding to p75 NTR, 
proBDNF also interacts with the receptor sortilin which acts as a co-receptor (Nykjaer et 
al., 2004). The proBDNF/p75 NTR/sortilin complex is known for promoting cell death 
through the Jun kinase and caspase dependent pathways (Teng et al., 2005). During 
development, p75 NTR activation promotes synaptic pruning of dendritic spines and axons 
via RhoA (Orefice et al., 2016; Singh et al., 2008). ProBDNF also regulates long-term 
depression (LTD), another form of activity dependent plasticity characterized by 
weakening synaptic signaling (Woo et al., 2005). A study published by Yang et al., 2014 
demonstrated that proBDNF overexpression in mice decreased dendritic spine density, 














Figure 1. BDNF TrkB and p75 NTR signaling pathways. Activation of TrkB by BDNF 
leads to transphosphorylation of tyrosine residues in the intracellular C-terminal domain. 
This leads to the activation of TrkB linked second messenger signaling pathways 
including PLCy (phospholipase C-gamma), MEK (mitogen-activated protein kinase 
kinase), and PI3-K (phosphatidyl inositol 3 kinase). These signaling pathways are 
downstream processes involved in cell survival, neuroplasticity, neurogenesis, and 
neuronal differentiation. Activation of p75 NTR by BDNF leads to apoptosis through the c-
Jun pathway.  
 
BDNF signaling is critical to many neurological functions. Importantly, BDNF 
signaling supports the development of dendritic arborizations and growth of dendritic 
spines (McAllister et al., 1995; Tyler and Pozzo-Miller, 2003). It is also responsible for 
modulating activity-dependent plasticity processes such as long-term potentiation (LTP) 
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through the PLC-y signaling pathway in hippocampal pyramidal neurons (Leal et al., 
2014; Minichiello et al., 2002; Pang et al., 2004; Sciarretta et al., 2010). In other 
structures such as the amygdala, a brain region that functions in fear response and 
memory, BDNF plays critical roles in the consolidation and extinction of fear memories 
(Li et al., 2017; Ou and Gean, 2007; Psotta et al., 2013). Moreover, BDNF plays multiple 
roles in the peripheral nervous system. During development, BDNF, NGF and NT-3 
together coordinate the survival of proprioceptive and nociceptive sensory neurons 
through their respective Trk receptors (Fan et al., 2000; Liebl et al., 1997; Robinson et 
al., 1996; Stephens et al., 2005; Valdés-Sánchez et al., 2010). For example, cultured 
trigeminal sensory neurons switch their reliance from BDNF and NT-3 to NGF at day 12 
of embryonic development (Buchman and Davies, 1993). In the cochlea, BDNF is 
critically responsible for the development of cochlear sensory nerves which innervate the 
inner hair cells of the organ of corti (Fritzsch et al., 2004; Johnson Chacko et al., 2017). 
BDNF deficient animals lose cochlear sensory innervation leading to hearing loss 
(Kersigo and Fritzsch, 2015; Schimmang et al., 2003). Interestingly, some studies show 
BDNF does not play a significant role in the survival of developing motor neurons (Jones 
et al., 1994; Liu et al., 1995). However, BDNF is involved in the maintenance of motor 
neurons in the mature nervous system and is suggested to improve locomotor function 
after spinal cord injury (Fang et al., 2017; Joseph et al., 2012).  
BDNF is synthesized in non-neuronal tissues such as skeletal muscle (Sakuma 
and Yamaguchi, 2011). Muscle-derived BDNF was initially discovered through its 
relationship with androgens and their synergistic rescue of the motor neurons innervating 
the spinal nucleus of the bulbocavernosus (SNB) and levator ani (LA) muscles (Al-
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Shamma and Arnold, 1997; Ottem et al., 2013; Yang and Arnold, 2000). The motor 
neurons innervating the SNB and LA muscles undergo apoptosis during perinatal 
development. A large population of neurons survive these apoptotic events in males, 
leading to a sexual dimorphism in relation to females. Castration in males retracts SNB 
and LA motor neurons, demonstrating the role of androgens in survival of these neural 
populations. Studies in which SNB motor neurons were axotomized, a reduction in 
androgen receptor expression was observed when connections between the neuron and 
muscle deteriorated. In axotomized neurons which maintained muscle innervation, AR 
expression was stabilized. Al-Shamma and Arnold, (1997) revealed retrograde transport 
provides support for AR expression. The authors then identified that BDNF leads to the 
survival of AR in axotomized motor neurons. Lastly, Yang and Arnold, (2000) castrated 
male rats in addition to axotomy of SNB motor neurons. The authors then administered 
BDNF alone to identify if it would rescue AR expression. Interestingly, BDNF by itself 
did not revive AR expression, however when it was administered with testosterone, AR 
expression was maintained. This data suggests that muscle-derived BDNF must be 
trafficked through retrograde transport to SNB motor neurons and behaves synergistically 
with testosterone to enhance AR expression and the survival SNB/LS motor units.  
Due to its many roles in the nervous system, BDNF has been linked to the 
pathology of several neurodegenerative and psychiatric diseases. The common Val66met 
single nucleotide polymorphism (SNP) in the BDNF gene, is linked to bipolar disorder 
along with clinical features of schizophrenia (Hong et al., 2011; Notaras et al., 2015). The 
mutation causes a valine to methionine substitution in the pro-domain of codon 66. The 
mutation is suggested to alter hippocampal morphology and lead to memory impairments 
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through aberrant trafficking and secretion of mature BDNF (Cao et al., 2016; Chen et al., 
2004; Egan et al., 2003; Hariri et al., 2003).  
Altered expression of BDNF, specifically a loss of the protein, is a recurring 
theme in pathology. For example, in patients with major depressive disorder (MDD), 
BDNF is reduced in the prefrontal cortex, amygdala, and blood serum (Lee et al., 2014). 
Additionally, patients with MDD who committed suicide also show lowered BDNF 
levels. In Alzheimer’s disease, Holsinger et al., (2000) identified a 3.4-fold decrease in 
BDNF mRNA in the parietal cortex of post mortem patients. Moreover, studies involving 
patients with schizophrenia also show decreased levels of BDNF in the hippocampus of 
post mortem tissue. In contrast, increased expression has been found in cortical regions in 
these individuals (Durany et al., 2001). Importantly, BDNF is diminished in Huntington’s 
disease (HD), a lethal autosomal dominant polyglutamine disease (Trottier et al., 1995). 
The CAG trinucleotide expansion in HD occurs in the huntingtin gene, causing a 
malformed huntingtin protein. The huntingtin protein is thought to play a role in dynein 
motor protein complexes (previously described) (Caviston et al., 2007; Caviston et al., 
2011). Moreover, mutant huntingtin protein disrupts retrograde vesicular transport of 
dynein motor proteins (Liot et al., 2013). Cargo vesicles containing BDNF/TrkB are not 
properly transported, leading to an absence of neurotrophic support and death of striatal 
neurons (Silva et al., 2015, Zuccato et al., 2001; Zuccato et al., 2008). Because BDNF is 
not synthesized by striatal neurons, they depend on retrograde transport of the 
neurotrophin obtained from synaptic targets.  
BDNF may be involved in ALS pathology. Because BDNF is trafficked via 
retrograde transport and given its roles in SBMA and Huntington’s disease pathology, it 
12 
 
becomes a good candidate for involvement in ALS pathogenesis. BDNF has been 
described as a potential therapeutic agent for the treatment of ALS. Korkmaz et al., 
(2014) demonstrated that a potent TrkB agonist improved ALS SOD1 symptoms in a 
transgenic mouse model. Moreover, exogenous administration of BDNF was also shown 
to revive in vitro cells with ALS derived cerebrospinal fluid (Shruthi et al., 2017). 
Recently, BDNF has been shown to regulate and increase the axonal localization of TDP-
43, a protein involved in ALS related cellular pathologies (Fallini et al., 2012).  
The primary objective of the Ottem laboratory research program is to investigate 
the role of muscle-synthesized BDNF in neuromuscular disease pathology. Cre-Lox 
recombination technology was used to delete the BDNF coding region in skeletal muscle 
of mice. This knockout model is accomplished through the breeding of two transgenic 
mouse lines. One mouse line carries the HSA-Cre gene derived from the P1 
bacteriophage. The human skeletal-actin (HSA) promoter was manipulated to drive 
transcription of the Cre recombinase enzyme exclusively in skeletal muscle. The other 
mouse line contains two artificially inserted LoxP sites located upstream and downstream 
from the BDNF coding region. LoxP-flanked (floxed) sites are 34bp sequences which 
will excise DNA through Cre-recombinase activity, if oriented in the same direction. 
When mice carrying the HSA-Cre gene are crossed with mice carrying BDNF floxed 
markers, the BDNF gene is deleted in skeletal muscle completely impairing expression 
(Figure 2). Muscle-derived BDNF knockout mice demonstrate a degenerative phenotype 
characterized by muscle weakness and diminished movement, similar to mouse models of 




Figure 2. Cre-Lox Recombination Technology. Cre recombinase shown above is driven 
by the human skeletal actin (HSA) promoter. When HSA-Cre mice are bred with mice 
carrying LoxP markers flanking the BDNF gene, the BDNF coding region is deleted from 
skeletal muscle (Dangremond, 2016).  
 
Previously, research performed by the Ottem research program has demonstrated 
that muscle-synthesized BDNF provides trophic support for innervating motor neurons 
via retrograde transport (Pomeroy, 2013). These data suggests that a loss or reduction in 
muscle-synthesized BDNF leads to a decrease in soma size. Moreover, Flourogold tracer 
was utilized to assess dendritic morphology. Fluorogold is a fluorescent tracing molecule 
which is trafficked in neurons via retrograde transport. Results from this study showed a 
reduction in labeling of motor neuron dendrites. However, it remained unclear if the 
truncated dendritic appearance was due to aberrant retrograde trafficking of fluorogold, 
truncated dendritic outgrowth, or experimental error from damaged tissue during 
cryosectioning. To identify if retrograde transport was disrupted in muscle deficient 
BDNF mice, ligations of the sciatic nerve were performed (Dangremond, 2016). 
Immunolabeling techniques were used to label phosphorylated neurofilament-H (NF-H-
P) and DCTN1 to identify if abnormal accumulation occurred in distal gastroc-associated 
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motor neurons. These data showed an accumulation of phosphorylated NF-H-P and 
DCTN1 at the distal dendrites of 120 day old mice. NF-H-P is a neurofilament subunit 
which is normally trafficked by retrograde transport. Because accumulation of NF-H-P 
and DCTN1 was identified immediately distal to the ligation site of the sciatic nerve, 
these data suggest a disruption in retrograde transport. Finally, an assessment of 
mitochondrial density at the neuromuscular junction using MitoTracker was performed. 
MitoTracker is a fluorescent molecule which labels live mitochondria through its 
membrane potential. Results from this study demonstrated a decrease in Mitotracker-
VAChT colocalization at the presynapse of 120 old knockout mice. The diminished 
labeling could be due to several factors which include diminished presynaptic surface 
area, non-labeled degenerated mitochondria, or that diminished BDNF/TrkB has 
impaired mitochondrial trafficking. Further investigation into the mitochondria density of 
muscle-deficient BDNF mice is required for understanding its role in this knockout 
model.  
While performing daily colony maintenance, it was discovered that BDNF floxed 
mice exhibited a distinct behavioral phenotype. Preliminary observations documented 
abnormal aggression and anxiety like behaviors, which was presented by infanticide and 
barbering (plucking or pulling of hair by a cage-mate or self). However, BDNF floxed 
mice were described as “normal and fertile” by Rios et al., (2001), the authors who 
originally engineered the transgenic strain. Unfortunately, they provided poor 
characterization of the BDNF floxed mouse behavioral phenotype. Furthermore, Clow 
and Jasmin (2007) used BDNF floxed mice in a skeletal-muscle knockout of BDNF. 
They also made no mention of abnormalities in the floxed mice in the Results section of 
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their publication. These authors did mention that aggressive behavior was demonstrated 
by BDNF+/- knockout mice (B6.129S4-BDNFtm1Jae/J) in which mothers frequently 
cannibalized their pups. An investigation into the characterization of the behavior of 
BDNF floxed mice was initiated to ensure the integrity of the muscle-derived BDNF 
knockout model. It was hypothesized that the behaviors exhibited by BDNF floxed mice 
were due to LoxP site interference, leading to BDNF influenced abnormalities of the 
nervous system.  
Laboratory rodents used in research must undergo comprehensive screening to 
establish a well characterized behavioral phenotype. Unless a detailed behavioral 
phenotype is created, the ability for an animal strain to yield quality research will be 
limited. The first comprehensive screening protocol was developed by Irwin (1968), in 
order to characterize animal behavior after pharmacological administration. The Irwin 
test and further developed functional observational batteries (FOB), have become the 
standard for pharmacology induced behavioral research (Gauvin et al., 2016; Markgraf et 
al., 2010; Monroe et al., 2011; Moser, 1990). As inbred strains and transgenic animals 
have become increasingly popular in research, comprehensive screening has become 
crucial for behavioral characterization and identification of abnormalities (Rogers et al., 
1997). SHIRPA (SmithKline Beecham Pharmaceuticals; Harwell, MRC Mouse Genome 
Centre and Mammalian Genetics Unit; Imperial College School of Medicine at St 
Mary’s, Royal London Hospital, St Bartholomew’s and the Royal London School of 
Medicine; Phenotype Assessment) was developed as a three stage protocol to 
characterize newly developed strains and transgenic mice. The primary stage described 
by SHIRPA consists of standard behavioral observations, often including those initially 
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described by Irwin (1968). The secondary stage utilizes comprehensive behavioral 
batteries to screen for pathology. Lastly, the tertiary stage is based on the results of the 
previous stages to gain more detailed information of neurological function. Because the 
literature does not provide a detailed behavioral phenotype for BDNF lox+/+ mice, we 
performed a 3 stage SHIRPA protocol to characterize BDNF lox+/+ mice. Stage 1: home 
cage observations and open-field test (See Ch.1); Stage 2: tail suspension test (See Ch.4); 






























BDNF 2lox mice originally described by Rios et al., (2001) were purchased from 
The Jackson Laboratory (Bar Harbor, ME). BDNF 2lox mice were generated from es cell 
clones (Figure 3). BDNF 2lox mice obtained from The Jackson Laboratory were originally 
developed on a BALB/c inbred strain. These BALB/c BDNF 2lox mice were later 
backcrossed with a mixed C57BL/6, 129Sv inbred strain due to increased aggression by 
mothers who cannibalized pups during colony generation. BDNF 2lox were then bred to 
produce homozygous BDNF 2lox/2lox (BDNF lox+/+) and heterozygous BDNF 2lox (BDNF 
lox+/-).  
Figure 3. BDNF lox generation. Three lox P sites represented by triangles were inserted 
into the wild-type BDNF allele along with a selection cassette. CRE recombinase was 
used to excise the selection cassette and one lox P site to create the BDNF 2lox allele 










Animals (male and female) were maintained according to NIH Guidelines for the 
Care and Use of Laboratory Animals and the Institutional Animal Care and Use 
Committee of Northern Michigan University. All procedures involving research animals 
strictly followed IACUC protocol #210 guidelines. All mice were housed in the animal 
facility at Northern Michigan University with controlled lighting (14hr lights on and 10hr 
lights off), temperature (approximately 21-23˚C) and fed ad libitum (Mazuri Rodent 
Chow: Land O’ Lakes Purina Feed LLC, Richmond, IN).  
Three animal genotypes were used in this study. BDNF lox+/+ mice were the target 
genotype of this study which contain two BDNF floxed alleles. BDNF lox+/- mice, used as 
an intermediate experimental genotype group, contain only one floxed BDNF allele. Wild 
type control mice used in this study were obtained from our HSA-CRE79 (Tg(ACTA1-
cre)79Jme) colony. These mice were negative (-/-) for the Cre-recombinase enzyme and 
were generated on a mixed C57BL/6 and 129Sv background. Mice were bred by allowing 
male and female mice to mate in a designated mating cage. Male mice were removed 
from the mating cage after 7 days. Mothers gave birth to pups approximately 18 days 
after fertilization. Pups were weaned at 25 days of age. Newly weaned pups were ear 
punched and given an animal identification number. The tissue sample taken during ear 
punching was used for PCR genotype analysis. 
 In order to properly identify the different mouse genotypes, end-point PCR and 
gel electrophoresis was utilized. BDNF lox+/+ and BDNF lox+/- mice were distinguished by 
the use of two primers. One primer binds upstream from the first LoxP site while the 
second binds to the middle of the gene coding region. The presence of the LoxP sites 
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were identified by the size of the PCR amplification products. Mice containing LoxP sites 
had an amplification product of 487 bp while mice negative for the LoxP markers had an 
amplification production of 437 bp (Figure 4). Analysis of the electrophoresis gel 
displayed a single band for homozygous BDNF lox+/+ mice and double banding for 
heterozygous BDNF lox+/- mice (Figure 5). A second PCR reaction using a different set of 
primers identified the Cre-recombinase gene. In this procedure, Cre-recombinase positive 
mice (Cre+/-) were not used and therefore genotyping was performed to ensure the 
absence of the gene. One pair of primers recognized GAPDH, a housekeeping gene found 
in all animals which served as a reaction reference. A second set of primers were used to 








Figure 4. PCR gel electrophoresis of BDNF wild-type. Lanes 1 and 2 show the wild-type 
(-/-) BDNF allele containing one 437 bp band. Lanes 3-6 show a heterozygous genotype 
(+/-) with one band at 487 bp representing the BDNF floxed allele and a second band at 
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Figure 5. PCR gel electrophoresis genotypes. Gel A shows BDNF Lox banding patterns. 
Lanes containing only one amplified band are homozygous for BDNF floxed markers and 
contain 487 bp (Lanes 1-8). Lanes containing two split bands are heterozygous in which 
the top band represents the BDNF floxed allele (487bp) and the bottom band represents 
the wild-type allele (437bp). Gel B shows banding for the presence of CRE recombinase. 
All sample lanes contain a band at 300bp for the house keeping gene GAPDH. Banding 

















Stage 1 of our SHIRPA protocol included home cage monitoring and general 
animal observations. Although simple, observations made while mice are in their home 
cage can establish baseline activity levels, as well as identify unique or abnormal 
characteristics such as stereotypy behaviors (SB) (Gross et al., 2012; Garner and Mason, 
2002; Powell et al., 1999). SBs are repetitive, excessive, non-goal oriented behaviors, 
observed in captive mammals. In rodents, many SBs have been identified and include 
route-tracing, cage-twirling, somersaulting, and bar mouthing. Moreover, SBs are 
observed in humans where they are associated with neuropsychiatric disorders such as 
autism, obsessive compulsive disorder (OCD), Giles de la Tourette’s syndrome, and 
schizophrenia (Figee et al., 2016; Péter et al., 2017). Human stereotypies are presented by 
the obsessive behaviors of OCD, tics of Tourette’s syndrome, and other repetitive motor 
movements. SB pathology is suggested to involve abnormalities in the CSPP (Cortico-
Striato-Pallido-Pontine) circuits of the basal ganglia. Although the direct pathology of SB 
basal circuits has not been thoroughly studied in rodents, the CSPP circuits have been 
well described in humans with OCD and Tourette syndrome (Burguière et al., 2015; 
McBride and Parker, 2015). 
The open-field test is a behavioral study used to analyze the locomotor function of 
rodents in a novel environment (Schäfer and Hermans, 2011; Tatem et al., 2014; Quarta 
et al., 2015; Wang et al., 2017). Because locomotor activity is a general indicator of the 
overall activity level of an animal, open-field can collect valuable data related to the 
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motor function and general well-being. Animal models designed to replicate symptoms of 
neuromuscular disease, exhibit locomotor deficits and hypoactivity during the open-field 
(Devon et al., 2006). In contrast, hyperactivity is observed in animals which exhibit 
ADHD-like behavior (McDonald et al., 1998). In addition to locomotor function, anxiety 
behaviors and basic memory function can also be detected from this test (Prut and 
Belzung, 2003; Quarta et al., 2015). Animals which spend more time around the 
periphery of the open-field arena in comparison to the center, may indicate increased 
anxiety. Furthermore, basic memory function may be demonstrated by exploratory 
behavior (Curzon et al., 2009). Animals which exhibit similar or increased exploratory 
behavior patterns during repeated open-field trials, may indicate reduced memory 
function. Together, home-cage observations and the open-field test, are used to 
effectively screen transgenic mice for basic intrinsic qualities.  
 
Methods 
Home cage observations were performed by observing the experimental animals 
in their designated housing cages. Housing cages were places on a table and recorded 
with a camera (GoPro Hero 4 Silver at 1080p resolution) for approximately 20 minutes. 
Measurements were taken in the animal facility with minimal disturbance. The animals 
were scored based on duration of activity and characterized by unique or abnormal 
behavior. General observation were made by observing various cages of each animal 
genotype, daily for approximately 5 minutes.  
The open-field test was performed by placing each mouse in the center of an 
open-field arena (a white plastic tub with 2’ L X 2’ W X 2’ H dimensions) while 
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documenting locomotor activity for a duration of 10 minutes. A GoPro camera (GoPro 
Hero 4 Silver at 1080p resolution) was fixed on a tripod and oriented above the open-
field arena to provide a recording. The open-field test was performed twice, first at 65 d 
and again at 165 d. Prior to testing, mice were acclimated to the behavioral 
experimentation room for 2 hours. The animals were isolated in the testing room once 
recording began to prevent external cues from altering behavior. Testing was performed 
between the hours of 4-6pm. The open-field arena was cleaned with 70% ethanol 
between trials. Measurement scoring was performed using Noldus EthoVision XT 
(version 7) software provided by Dr. Adam Prus, Department of Psychological Science 
Northern Michigan University. Data analysis scored the mice for total distance traveled 
and mean velocity during the 10 min period. Data analysis for mean velocity was 
calculated based on the average velocity each mouse traveled throughout each trial, and 
then averaged per group. Statistical analysis was performed using One-way analysis of 
variance (ANOVA) and Tukey’s multiple comparison test for the three genotypes at 65 d 
and 165 d open-field. An unpaired t-test was used to compare total distance traveled of 
BDNF lox+/+ mice at 65 d versus 165 d.  
 
Results 
 Statistically significant differences were not shown for home cage behavior across 
all groups. However, general observations revealed anecdotal evidence of stereotypy 
behaviors (SBs) in BDNF lox+/+ mice. The SBs observed included somersaulting (back 
flipping) and patterned running (route tracing). These behaviors were not consistent 
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throughout the BDNF lox+/+ colony, but were identified per generation. No stereotypy 
behaviors were observed in BDNF lox+/- mice or BDNF lox-/- control groups.  
Results for the open-field test performed at 65 d showed a significant difference 
between BDNF lox+/+ vs BDNF lox-/- mice for both mean velocity (F(2,21)=6.39, p<0.01)  
and total distance traveled [(F(2,21)=6.243, p<0.01; Figure 6)]. BDNF 
lox+/+ mice 
demonstrated a decrease in mean velocity and total distance traveled compared to BDNF-
/- mice. BDNF lox+/+ mice also demonstrated a significantly decreased mean velocity 
(F(2,21)=6.39, p<0.05) and total distance traveled (F(2,21)=6.243, p<0.05) in comparison to 
BDNF lox+/- mice at 65 d. No significant differences were observed between BDNF lox+/- vs 
BDNF lox-/- mice. The open-field test performed at 165 d showed different results. BDNF 
lox+/+ mice demonstrated a significant increase in mean velocity (F(2,21)=34.66, p<0.001) 
and total distance traveled [(F(2,21)=34.61, p<0.001; Figure 6)] compared to BDNF 
lox-/- 
mice. BDNF lox+/+ mice also demonstrated a greater mean velocity (F(2,21)=34.66, p<0.001) 
and total distance traveled [(F(2,21)=34.61, p<0.001; Figure 6)] compared to BDNF
 lox+/- 
mice at 165 d. No significant difference was found between BDNF lox +/- versus BDNF lox-
/- mice. Additionally, BDNF lox+/+ mice significantly increase total distance traveled at 165 










Figure 6. Mean velocity and total distance traveled at 65 d and 165 d open-field. (A & B) 
BDNF lox+/+ mice at 65 d showed a decreased mean velocity (F(2,21)=6.39, p<0.01) and 
total distance traveled (F(2,21)=6.243, p<0.01) in comparison to BDNF 
lox-/- mice as well as 
a decrease in mean velocity (F(2,21)=6.39, p<0.05) and total distance traveled 
(F(2,21)=6.243, p<0.05) compared to BDNF 
lox+/- mice. (C & D) At 165 d, BDNF lox+/+ 
demonstrated a greater mean velocity (F(2,21)=34.66, p<0.001) and total distance traveled 
(F(2,21)=34.61, p<0.001) in comparison to BDNF 
lox-/-. BDNF lox+/+ mice demonstrated a 
significant increase in mean velocity (F(2,21)=34.66, p<0.001) and total distance traveled 
(F(2,21)=34.61, p<0.001) compared to BDNF 
lox+/- mice. Error bars represent standard error 
































































































Figure 7. Total distance traveled of BDNF lox+/+ mice at 65 d vs 165 d. Significant 
difference is shown between 65 d and 165 d (t(14)=4.424,  p<0.0006) where mice traveled 
a greater distance at 165 d during the open-field test. Error bars represent standard error 
of the mean. n=8.  
 
Discussion 
 As previously described by our results, general animal observations revealed that 
stereotypy behaviors (SB) were present in the BDNF lox+/+ colony. SBs are thought to 
arise from environmental stress due to captivity. BDNF lox+/+ mice are caged in standard 
rodent housing, a classic captive environment at risk for development of SBs. 
Interestingly, BDNF lox+/+ mice were the only genotype to develop SBs, which suggests 
that mice containing homozygous LoxP markers may be predisposed for SB 
development. Increased environmental stress is also thought to play a role is SB 
development which may indicate higher stress levels in this transgenic line. Additionally, 
mice demonstrating stereotypy behaviors suggests possible abnormalities in basal CSPP 
circuitry.   
BDNF lox+/+ Total Distance
 65 d vs 165 d


















The results for the 65 d open-field test show a decrease in locomotion for the 
BDNF lox+/+ mice in comparison to BDNF lox-/- and BDNF lox+/- mice. This indicates a 
decrease in exploratory behavior and suggests possible locomotor deficits. Interestingly, 
our results for the 165 d open-field demonstrates an increase in total distance traveled for 
BDNF lox+/+ mice. This increase was not only higher in comparison to BDNF lox+/- and 
BDNF lox-/- mice at 165 d, but significantly higher than the total distance traveled at 65 d. 
These data do not support the presence of locomotor deficits in BDNF lox+/+ mice. 
Alternatively, the increase in exploratory behavior demonstrates hyperactivity. This data 
could also interpret possible memory deficits due to the increased exploratory behavior 
demonstrated at 165 d in relation to the 65 d open-field.  
 An important observation was made while performing the open-field test. During 
transfer of mice to the arena, BDNF lox-/- mice quickly and aggressively climbed their tail 
towards the hand. This behavior was not demonstrated by BDNF lox+/+ mice which 
struggled to reach their tail. Upon closer investigation, we found BDNF lox+/+ mice 
displayed an abnormal plantar reflex. This was presented by limb retraction while mice 
were suspended from their tail. This discovery prompted a full tail suspension study 














 Tail suspension is a test validated to screen the plantar reflex of uncharacterized 
mouse strains for neuropathy (Rogers et al., 1997; Rogers et al., 2001). Testing is 
performed by suspending mice by their tail while observing the plantar reflex. Healthy 
animals with a normal plantar reflex, splay their limbs outward in a lateral orientation 
from the body (Figure 8 A). Abnormal plantar reflex is presented by retraction of the hind 
limbs (sometimes forelimbs) toward the midsagittal body plane, known as clasping 
(Figure 8 B and 8 C). Limb clasping is observed in mouse models with motor neuron 
disease such as ALS and Spinal Muscular Atrophy (Piras et al., 2017; Shinzawa et al., 
2008; Takahashi et al., 2010; Miyagishi et al., 2012). For example, SOD1 mutant mice 
representing an ALS model, show hind limb clasping with stiff leg paresis (Filali et al., 
2011; Hatzipetros et al., 2015). Additionally, a loss of proprioceptive sensory neurons 
and their associated muscle spindle fibers, can also lead to limb clasping (Chen et al., 
2007; Dupuis et al., 2009; Zhao et al., 2016).  
Hind limb clasping due to proprioceptive sensory neuropathy is observed in the 
mutant mouse strains Loa, Cra1, and Swl (Chen et al., 2007; Dupuis et al., 2009; Zhao et 
al., 2016). All three strains contain mutations in the heavy chain 1 gene (Dync1h1) of the 
molecular motor dynein. Offspring of these mutant strains demonstrate autosomal 
dominant inheritance, in which mice homozygous for Dync1h1 mutations (Loa/Loa, 
Cra1/Cra1, Swl/Swl) are embryonic lethal and heterozygous genotypes (Loa/+, Cra1/+, 
Swl/+) are viable with a normal lifespan. Hafezparast et al., (2003) first characterized the 
30 
 
origin of hind-limb clasping in Loa/+ and Cra1/+ mice. Loa and Cra1 mice arose from 
N-ethyl-N-nitrosourea-induced missense mutations at residues F580Y and Y1055C 
(respectively) in the cargo-binding domain of Dync1h1. The authors concluded that hind 
limb clasping was due to motor neuron loss from aberrant dynein controlled retrograde 
transport. A follow-up study investigated the hind limb clasping of Swl/+ mice, another 
strain harboring a nine base pair deletion between residues 1040-1043 in the cargo-
binding domain of Dync1h1 (Chen et al., 2007).  This study identified a significant loss 
of lumbar proprioceptive dorsal root ganglion neurons, along with a significant reduction 
of muscle spindle fibers. Interestingly, motor neurons in the anterior horn of Swl/+ mice 
were left functional and intact. The authors further demonstrated that Loa/+ mice also 
show early-onset proprioceptive sensory degeneration combined with late-onset motor 
neuron loss. Countering the result of Hafezparast et al., (2003) Cra1/+ mice also display 
early-onset proprioceptive sensory loss without motor neuron involvement (Dupuis et al., 
2009). These discrepancies between the loss of sensory and motor neurons is reviewed by 
Schiavo et al., (2013).  
 
Methods 
Mice were suspended by their tail for 60 s while recorded with a GoPro camera 
(GoPro Hero 4 Silver at 720p resolution). The tail suspension test was performed at 60 d, 
90 d, 120 d, and 150 d for all three mouse genotypes (BDNF lox+/+, BDNF lox+/-, and 
BDNF lox-/-). Clasping behavior was scored as follows: 0-1= no clasping; minor clasping, 
1-2= moderate clasping, 2-3=severe clasping. Partial scoring of 0.25, 0.5, and 0.75 was 
given to increase score accuracy. Clasping scores were assigned if limbs clasped for more 
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than 5 sec. One way ANOVA and Tukey’s multiple comparison test were used for data 
analysis.   
 
 Results: 
Table 1 shows the average clasping scores for the three mouse genotypes (BDNF 
lox+/+, BDNF lox+/-, and BDNF lox-/-). BDNF lox+/+ mice had an initial average clasping score 
of 1.56 at 60 d, compared to 0.75 and 0.0 for BDNF lox+/- and BDNF lox-/- respectively. At 
90 d, average clasping increased to 2.31 and 0.94 for BDNF lox+/+ and BDNF lox+/- mice 
respectively. Further clasping progression from an average score of 2.75 to 2.78 was 
observed in BDNF lox+/+ mice at 120 d and 150 d, whereas the BDNF lox+/- genotype only 
reached a score of 1.13 at 120d and 150 d. The BDNF lox-/- control genotype showed an 
average clasping score of 0.19 at 150 d.  
The tail suspension test performed at 60 d showed significantly greater average 
clasping in BDNF lox+/+ mice compared to BDNF lox-/- mice [(F(2,21)=7.483, p<0.01; Figure 
9 A)]. At 90 d, BDNF lox+/+ mice demonstrated significantly greater average clasping in 
comparison to BDNF lox+/- mice (F(2,21))=16.03, p<0.01) and BDNF 
lox-/- mice 
[(F(2,21)=16.03, p<0.001; Figure 9 B)]. At 120 d, average clasping for BDNF 
lox+/+ mice 
were significantly greater in comparison to BDNF lox+/- mice (F(2,21)=34.72, p<0.001) and 
BDNF lox-/- mice [(F(2,21)=34.72, p<0.001; Figure 9 C)]. BDNF 
lox+/- mice demonstrated a 
significantly greater average clasping compared to BDNF lox-/- mice [(F(2,21)=34.72, 
p<0.01; Figure 9 C)]. Lastly, BDNF lox+/+  mice showed significantly greater average 
clasping at 150 d in comparison to BDNF lox+/- mice (F(2,21)=27.86, p<0.001) and BDNF 
lox-/-  mice [(F(2,21)=27.86, p<0.001; Figure 9 D)]. BDNF 
lox+/- mice also demonstrated 
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significantly greater average clasping in comparison to BDNF lox-/- mice at 150 d 
[(F(2,21)=27.86, p<0.05; Figure 9 D)].  
Figure 8. Tail suspension test clasping levels. Normal plantar reflex is demonstrated by 
lateral splaying of limbs from body axis (A). Moderate Clasping of 1 hind limb indicated 









Table 1. Average clasping scores.  
Average clasping scores from the tail suspension test are shown for the three mouse 
genotypes at 60 d, 90 d, 120 d, and 150 d. Clasping scores were rated from 1-3 with 




Figure 9. Average clasping scores at 60 d, 90 d, 120 d, and 150 d for three mouse 
genotypes. (A) BDNF lox+/+ mice showed increased average clasping compared to BDNF 
lox-/- at 60 d (F(2,21)=7.483, p<0.01). (B) Average clasping at 90 d for BDNF 
lox+/+ mice are 
significantly greater than BDNF lox+/- mice (F(2,21)=16.03, p<0.01) and BDNF 
lox-/- mice 
(F(2,21)=16.03, p<0.001). (C) At 120 d, BDNF 
lox+/+ mice showed increased average 
clasping compared to BDNF lox+/- mice (F(2,21)=34.72, p<0.001)  and BDNF 
lox-/- mice 
(F(2,21)=34.72, p<0.001). BDNF
+/- mice showed increased average clasping compared to 
BDNF lox-/- mice (F(2,21)=34.72, p<0.01). (D) At 150 d, BDNF 
lox+/+ mice demonstrated 
increased average clasping compared to BDNF lox+/- mice (F(2,21)=27.86, p<0.001) and 
BDNF lox-/- mice (F(2,21)=27.86, p<0.001). BDNF
+/- mice also showed increased average 
clasping compared to BDNF lox-/- mice at 150 d (F(2,21)=27.86, p<0.05). Error bars 
represent standard error of the mean. All genotypes n=8.  
Genotype 60 Day 90 Day 120 Day 150 Day
BDNF lox +/+ 1.56 2.31 2.75 2.78
BDNF lox +/- 0.75 0.94 1.13 1.13

























































































 Data from tail suspension showed progressive hind limb and forelimb clasping 
deficits in BDNF lox+/+ mice.  Moderate clasping was initially present in BDNF lox+/+ mice 
at 60 d, and progressed to severe clasping impairments by 90 d. BDNF lox+/- mice 
demonstrated moderate clasping which plateaued at 90 d. BDNF lox-/- control mice only 
began to show low clasping impairments at the 150 d test, suggesting age related deficits. 
During the tail suspension trials, BDNF lox-/- control mice behaved aggressively and 
consistently climbed their tail to the researcher’s hand. The control mice often had to be 
distracted by an object, such as a pen, to keep them from ascending their tail. In contrast, 
BDNF lox+/+ mice were more docile and demonstrated a lack of core muscle strength when 
attempting to climb their tail which often resulted in fatigue. Some BDNF lox+/+ mice 
would clasp their limbs while dangling with very little movement. Clasping in BDNF 
lox+/+ mice would often begin with hind limbs splaying at odd angles with slight axial 
clasping. This progressed to full limb clasping towards the axial plane as they aged. 
Ultimately, this data provides us with evidence that motor or sensory neuropathy is 
present in BDNF lox+/+ mice through the presence of limb clasping. 
Interestingly, the clasping deficits presented by our BDNF lox+/+ genotype are 
identical to the limb clasping of our BDNF skeletal muscle knockout mice (unpublished 
data). These data suggests that limb clasping is correlated with the presence of LoxP sites 
flanking the BDNF coding region and may not be from the absence of muscle-











Prepulse inhibition (PPI) of the acoustic startle response is a paradigm used to 
measure sensorimotor gating, the brain’s ability to properly gate sensory and motor 
information (Graham, 1975). PPI is performed by the generation of a weak prepulse 30-
500 ms before a strong startle pulse. The given prepulse attenuates the startle response 
amplitude. PPI’s attenuation of the startle response is an involuntary reflex conserved 
among vertebrates (Braff et al., 2001a; Geyer et al., 2002). During acoustic PPI testing, 
the pulses are bursts of white noise used to fill a range of acoustic frequencies. Acoustic 
PPI in vertebrates with intact sensorimotor gating demonstrate a correlation of increased 
startle attenuation to an increase in prepulse dB levels. Deficits in PPI are presented by 
impairment of the prepulse attenuation of startle amplitude. In humans, acoustic PPI is 
measured through the eye-blink component of the startle reflex, measured by 
electromyography of the orbicularis oculi muscle. In rodents, acoustic PPI is measured 
through startle movement detected by a platform sensor.   
Several neuropsychiatric disorders have been identified with PPI deficits 
including schizophrenia, Tourette’s syndrome, Huntington’s disease, and obsessive-
compulsive disorder (OCD) (Hoenig et al., 2005; Kohl et al., 2013; Swerdlow et al., 
1995; Swerdlow, 2013). Schizophrenia was the first disease identified with PPI deficits 
and is the standard phenotype for impaired sensorimotor gating (Braff et al., 2001b; 
Swerdlow et al., 1990). Moreover, rodent strains with reduced PPI are used to represent a 
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schizophrenia-like endophenotype (Powell et al., 2009). This endophenotype has been 
useful in pharmacology research for the development of drug treatments such as 
antipsychotics (Geyer et al., 2001). 
The PPI reflex and startle response are regulated by complex physiological 
systems and circuits which are not fully understood. Notably, PPI and the acoustic startle 
response are not regulated by the same circuits (Sandner and Canal, 2007). The acoustic 
startle response involves signaling between the cochlear root neurons, the caudal pontine 
reticular nucleus (PnC) and ventral tegmental area (Lauer et al., 2017). Acoustic PPI is 
thought to inhibit the PnC and involve signaling between the inferior colliculus and 
superior colliculus which innervate the pedunculopontine tegmental nucleus. Many 
studies further support the involvement of basal forebrain circuits which include the 
limbic cortex, striatum, pallidum, and pontine tegmentum (limbic CSPP circuit) in PPI 
(Swerdlow et al., 1992; Swerdlow et al., 2001; Swerdlow et al., 2016). Important limbic 
structures include the hippocampus, amygdala, nucleus accumbens, and thalamus (Miller 
et al., 2010). More specifically, research has identified the involvement of dopaminergic, 
serotonergic, and noradrenergic systems in PPI. For instance, the dopaminergic agonists 
apomorphine and D-amphetamine for instance disrupt PPI in rats acting through the D2 
receptor. Interestingly, D2 agonists do not disrupt PPI in some mouse strains which 
instead respond to D1 agonists (Ralph and Caine, 2005; Ralph and Caine, 2007). The 
serotonerigic system has also demonstrated importance in PPI modulation through 
several receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A, however, similar to the 
dopamine system, modulation appears to be strain and species specific (Dulawa et al., 
2000; Dulawa and Geyer, 2000; Varty et al., 1999). Notably, 5-HT2A receptor agonists 
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disrupt PPI, whereas 5-HT2A antagonistic antipsychotics, restores PPI (Sipes and Geyer, 
1995). Moreover, noradrenergic forebrain innervation is shown to support sensorimotor 
gating regulation. Stimulation of the locus coeruleus (LC), the primary source of 
forebrain norepinephrine (NE), produces distinct PPI disruption (Alsene and Bakshi, 
2011). A follow-up study showed that activation of several regions normally innervated 
by the LC, particularly the mediodorsal thalamus, reduce PPI (Alsene et al., 2011). In 
conclusion, the systems responsible for PPI regulation are very complex and demonstrate 
variances across species which further complicates our understanding of PPI.  
Due to the correlation of altered BDNF regulation in neurological diseases such as 
schizophrenia and Huntington’s disease, BDNF may also have implications in the PPI 
reflex. Takahashi et al. (2006) demonstrated that phencyclidine (PCP) administration 
increased expression of BDNF which correlated with reduced PPI, characteristic of 
schizophrenic endophenotype. Another study showed BDNF injections restored PPI in 
DBA/2J mice, an inbred mouse strain with impaired PPI (Naumenko et al., 2013). 
Interestingly, BDNF was not shown to impair PPI in rats with 50% reduced BDNF 
expression in neural tissue (van den Buuse et al., 2017). However, mice containing the 
Val66Met BDNF mutation show reduced PPI, suggesting that impairment of activity-
dependent trafficking of BDNF may be responsible (Notaras et al., 2017).  
There are many factors to take into consideration when performing a PPI study 
(Lauer et al., 2017). For instance, different strains of mice and rats have varying basal 
levels of PPI and acoustic startle (Geyer et al., 2002). Importantly, certain mouse strains 
including C57BL/6 mice develop age related hearing deficits. These strain specific 
variables have the potential to significantly alter results, negatively impacting a study. It 
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is crucial to be fully aware of the phenotypic characteristics of the animal strain selected 
for research which may impact a PPI study.  
 
Methods 
The Startle Reflex system (MED Associates, Inc.) was used to measure 
sensorimotor gating in mice via PPI. The Startle Reflex system hardware consisted of a 
startle reflex cabinet, sound-attenuating cubicle, PHM-255A startle platform attenuator, 
and PHM-250B unit (Figure 10). Hardware was configured as described by MED 
Associates Startle Reflex Manual (SOF-825). Hardware was connected to a PC computer 
for use with MED Associates Startle Reflex software. The startle chamber was arranged 
on a vibration isolation table to prevent vibration interference. The Startle Reflex system 
was configured in a separate, isolated room designated for behavioral studies within the 
animal facility. Only one startle chamber was used for experimentation. The Startle 
Reflex system was supplied by the Department of Psychological Science, Northern 
Michigan University.  
Figure 10. PPI Startle Reflex system (MED Associates, Inc.). The image includes the 
startle reflex cabinet, sound-attenuating cubicle, PHM-255A startle platform attenuator, 
and PHM-250B unit. 
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The Startle Reflex system was calibrated prior to each session per animal. This 
included both auditory and input calibration as described by the MED Associates Startle 
Reflex Manual (SOF-825). Acoustic PPI was performed using various dB white noise 
bursts. PPI testing was administered using two separate sessions. A baseline session was 
first administered to all mice (68 d ± 2 d) 2 days before the experimental testing session. 
The purpose of the baseline session is to acclimate animals to the PPI chamber. Exposure 
to the PPI baseline session reduces the possibility of exaggerated startle response. The 
baseline session also allowed for adjustments to the startle chamber equipment and 
computer program, to ensure accurate data processing. All animals were subject to the 
trials described in both the baseline and testing sessions. Mice were acclimated to the PPI 
facility for 2 hours prior to baseline and testing sessions. The baseline session consisted 
of 1 block with a duration of 15 min. 65 dB of white noise was sustained by the speaker 
throughout the session. After 5 min, the computer was programmed to generate either a 
120 dB pulse of 40 ms or a 77 dB pulse of 20 ms, followed 100 ms later by a 120 dB 
startle pulse. 
The testing session was performed on all mice (70 d ± 2 d) 2 days after the 
baseline session and contained 65 dB white noise sustained throughout the session. The 
testing session consisted of 3 blocks. Block 1 began after 5 min and consisted of 5, 120 
dB pulses, 40 ms in duration, and separated by 15 s. Block 2 consisted of 50 randomized 
(programmed and consistent for all animals) experimental trials separated by 15 s. All 
experimental data was collected from Block 2. Block 3 consisted of 5, 120 dB pulses 




Table 2. PPI Block 2 trials. 
1.) 10 trials of a 68 dB prepulse (20 ms) followed 100 ms later by a 120 dB 
pulse (40 ms) 
2.) 10 trials of a 71 dB prepulse (20 ms) followed 100 ms later by a 120 dB 
pulse (40 ms) 
3.) 10 trials of a 77 dB prepulse (20 ms) followed 100 ms later by a 120 dB 
pulse (40 ms) 
4.) 10 trials of only a 120 dB pulse (40 ms) 
5.) 10 trials administering no pulse 
 
PPI Block 2 consisted of 10 trials of each of the following prepulses followed by a startle 
pulse of 120 dB: (1) 68 dB, (2) 71 dB, (3) 77dB, (4) no prepulse, and (5) no prepulse no 
startle.  
 
 Data analysis was performed from raw PPI data extracted from MED Associates 
software and compiled in Microsoft Excel. Peak Values from the startle cue was used for 
data analysis. Startle data was arranged for each prepulse dB rating per animal subject 
and compared against each group. Box and Whisker plots were used to remove statistical 
outliers. Prepulse was calculated as percent PPI ((1-(mean PPI/mean peak startle)*100). 
One-way analysis of variance (ANOVA) was used to calculate statistical significance.  
 
Results 
 Figure 11 shows peak startle magnitudes without a prepulse for the three 
genotypes (BDNF lox+/+, BDNF lox+/-, and BDNF lox-/-). There was no significant difference 
between peak startle values across the three genotypes. No significant differences were 
found between BDNF lox+/+, BDNF lox+/-, and BDNF lox-/- mouse genotypes at 68 dB 
prepulse startle (Figure 12). Results from the 71 dB prepulse startle also showed no 
significant differences between animal groups (Figure 12). Interestingly, BDNF lox-/- mice 
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demonstrated reduced PPI (percent PPI) characterized by an increase in startle amplitude 
at the 77 dB prepulse trail. A significant increase in PPI (percent PPI) was shown 
between BDNF lox+/+ mice versus BDNF lox-/- mice (F(2,21)=13.01, p< 0.001) as well as 
between BDNF lox+/- mice versus BDNF lox-/- mice [(F(2,21) =13.01, p < 0.01; Figure 12)]. 
There was no significant difference found between BDNF lox+/+ mice versus BDNF lox+/- 
mice (Figure 12).  
 
 
Figure 11. Startle magnitude without prepulse. Peak startle values from a 120 dB 
whitenoise startle burst was compared across three genotypes (BDNF lox+/+, BDNF lox+/-, 
and BDNF lox-/- mice). Error bars indicate standard error of the mean. There was no 






























Figure 12. Prepulse inhibition of acoustic startle response. PPI was performed across 
three mouse genotypes BDNF lox+/+, BDNF lox+/-, and BDNF lox-/- mice at 68 dB (A), 71 
dB (B), and 77 dB (C). BDNF lox+/+ mice (F(2,21)=13.01, p<0.001) and BDNF 
lox+/- mice 
(F(2,21)=13.01, p<0.01) demonstrated significantly increased percent PPI at 77 dB 
prepulse in comparison to BDNF lox-/- mice. Error bars indicate standard error of the 

























































































Results from the acoustic PPI test showed no differences in prepulse startle 
conditions at 68 or 71 dB. This could be due to the inability of mice to sense low dB 
prepulse tones over the facility venting fans. Notably, the 77 dB prepulse startle condition 
significantly decreased percent PPI in BDNF lox-/- mice. An increase in percent PPI was 
observed in both BDNF lox+/+ and BDNF lox+/- mice, which suggests an overactive PPI 
response in these genotypes. These results show functional but potentially hypersensitive 
sensorimotor gating in BDNF lox+/+ and BDNF lox+/- mice compared to BDNF lox-/-. This 
could be further explained by possible abnormalities in the forebrain CSPP and 
noradrenergic pathways which regulate sensorimotor gating. These data provides a 
correlation between the presence of LoxP sites which flank the BDNF gene and the 
increase in PPI startle reflex. Further analysis of the integrity of the CSPP circuits in 
BDNF lox mice needs to be further evaluated to support this data.  
We must take note that the BDNF lox-/- control mice used in this study were 
C57BL/6 mice. BDNF lox+/+ and BDNF lox+/- were also backcrossed with BDNF lox-/- mice 
as described in Chapter 2. C57BL/6 mice are known to have age related hearing deficits 
which could explain their reduced PPI response at 77 dB. Other variables influencing our 












 The primary focus of the Ottem research lab is to investigate the role of muscle-
synthesized BDNF at the neuromuscular junction. Cre-Lox recombination was used to 
excise the BDNF coding gene from skeletal muscle in mice. It was noticed that BDNF 
lox+/+ mice demonstrate abnormal and uncharacterized phenotypic behaviors. To scrutinize 
the integrity of the muscle-derived BDNF knockout  mouse model, home cage 
monitoring observations, open-field test, tail suspension test, and PPI were utilized to 
provide a well characterized behavioral phenotype for BDNF lox+/+ transgenic mice. 
In Chapter 3, general observations of the BDNF lox+/+ mouse colony revealed 
anecdotal evidence of stereotypy behaviors such as somersaulting (back flipping) and 
patterned running (route tracing). Neither of these behaviors were observed by BDNF 
lox+/-or BDNF lox+/+ genotypes. These observations may suggest increased stress and a 
predisposition for the development of stereotypy behaviors (SB) in BDNF lox+/+ mice. A 
more thorough analysis could consist of nocturnal monitoring for activity and SB. Next, 
the open-field test showed an increase in locomotor behavior in BDNF lox+/+ mice 
compared to controls. These results suggest BDNF lox+/+ mice do not have motor related 
impairment. BDNF lox+/+ mice also increased their total distance traveled at the 150 d trial 
in comparison to the 65 d trial, which may imply some form of memory deficit and 
hyperactivity. Additionally, while performing the open field test, the presence of limb 
clasping was discovered in BDNF lox+/+ mice. 
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Tail suspension performed in Chapter 4 revealed progressive forelimb and hind 
limb clasping impairments in BDNF lox+/+ mice. We showed that severe clasping (Ave. 
score 2.31/3) was reached by 90 d BDNF lox+/+ mice. Only moderate clasping (Ave. score 
1.13/3) was observed in BDNF lox+/- mice at 150 d and low clasping (Ave. score 0.19) 
deficits were observed in our control mice, appearing to be age related. These data 
strongly suggests some form of motor or sensory neuropathy is present in BDNF lox+/+ 
mice. Future studies should perform tail suspension on newly born mice and at 30 d to 
identify the onset of clasping deficits.  
In Chapter 5, we showed increased PPI in BDNF lox+/+ and BDNF lox+/- mice at the 
77 dB prepulse startle in comparison to BDNF lox-/- mice. These results demonstrate a 
hypersensitive sensorimotor gating reflex that could be due to alterations in the CSPP 
circuits. These results suggest a possible correlation between increased PPI and the 
presence of the LoxP sites flanking the BDNF coding region. Because BDNF plays roles 
in maintenance and plasticity of the basal ganglia, there is evidence that altered BDNF 
expression and function could alter the basal forebrain CSPP circuits involved in 
sensorimotor gating (Jing et al., 2017; Liot et al., 2013). The presence of stereotypy 
behaviors observed in Chapter 3, which are suggested to involve deficits in basal circuits, 
provides further support for altered CSPP circuitry. Following studies should include PPI 
trials utilizing prepulses above 77 dB (ex. 80 dB, 83 dB, 86 dB) which could validate a 
hyper responsive PPI reflex in BDNF lox+/+ and BDNF lox+/- mice.  
Together, our results suggest BDNF lox+/+ mice exhibit neuropathy which 
primarily resembles a loss of proprioceptive sensory neurons. This is supported by the 
absence of motor related impairments taken from the open-field test, combined with the 
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presence of severe clasping deficits identified from tail suspension. As previously 
described, Loa, Cra, and Swl mice with mutations in dynein heavy chain Dync1h1, 
demonstrate hind limb clasping due to embryonic loss of proprioceptive dorsal root 
ganglia (Chen et al., 2007; Dupuis et al., 2009; Zhao et al., 2016). Importantly, aberrant 
dynein trafficking of NGF was shown to cause significant apoptosis of cultured Swl/+ 
sensory neurons. This provides a mechanism for neurotrophin related proprioceptive 
sensory neuropathy. We suggest that the 34 bp LoxP sites flanking the BDNF coding 
region of BDNF lox+/+ mice, interferes with BDNF transcription leading to sensory 
neuropathy and limb clasping. Here we provide two possibilities. (1) Because BDNF 
plays important roles in the development of sensory neurons, we postulate neuropathy is 
due to early-onset loss of sensory neurons (Buchman and Davies, 1993; Liu et al., 1995; 
Zhao et al., 2016). This could occur through over expression of proBDNF which prunes 
sensory neurons by p75 NTR signaling. Alternatively, if mature BDNF was under 
expressed, its activation of survival signals via TrkB would be hindered. (2) Because our 
data demonstrated limb clasping deficits which progressed over time, an alternative is 
that late-onset neuropathy is induced through an absence of maintenance signaling via 
TrkB cascades. Additionally, both of these possibilities could involve dysfunctional 
retrograde transport of BDNF. The behavioral data provided by this research can only 
allow for speculations to be made regarding the cellular and molecular pathologies of 
BDNF floxed mice. Further investigation of BDNF expression levels, the density of 
dorsal root ganglia, ventral spinal roots, and muscle spindle fibers is required. Moreover, 
we cannot rule out motor neuron related pathologies. To explore these possibilities 
quantification of TrkB and p75 receptor expression/labeling should be performed to aid 
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in the identity of the present form of BDNF. To explore the possibility of disrupted 
retrograde transport, BDNF should be supplemented for NGF in cultured BDNF lox+/+ 
neurons in campenot chambers (compartmentalized neuronal culture) described by Zhao 
et al., (2016). Lastly, the Hoffman reflex test which measures the functional activity of 
proprioceptive sensory neurons could be performed to show if sensory neurons exhibit 
normal or reduced activity in vivo (Chen et al., 2007; Gajewska-Woźniak et al., 2013).  
The overall significance of our data is illuminated upon reviewing Rios et al., 
(2001). Previously, the authors utilized BDNF lox+/+ mice to engineer a heterozygous 
knockout of BDNF in neural tissue via Cre-Lox recombination. The authors stated “Mice 
carrying the floxed BDNF allele (BDNF 2lox) were generated using targeted ES cell 
clones and homozygous mice for this allele were normal and fertile”. This statement 
refers to mice with a single BDNF floxed allele, however, their research model uses 
homozygous BDNF floxed alleles (BDNF lox+/+). Their results show increased 
hyperactivity, intermale aggression, and obesity in their conditional mutants (BDNF 
lox+/+/93). Our data strongly supports the notion that BDNF lox+/+ mice are not normal and 
demonstrate an abnormal behavioral phenotype. We argue that the hyperactivity and 
aggressive behaviors demonstrated by the BDNF conditional mutants (BDNF lox+/+/93) 
may be partially the result of interference from the LoxP sites flanking the BDNF gene. 
This is supported by the increased, late-onset locomotor activity of BDNF lox+/+ mice 
during the 150d open-field and the presence of stereotypy behaviors. These results 
highlight the possibility that some of the pathologies observed in our skeletal-muscle 
synthesized BDNF knockout mice are due to the BDNF LoxP site. Future studies should 
compare BDNF lox+/+ mice to skeletal-muscle synthesized BDNF knockout mice in tail 
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suspension, cell count of dorsal and ventral root, and a comparison of muscle tissue 
including muscle spindle fiber quantification. In conclusion, we have uncovered a 
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